Drugs / BAT1006
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05414136 | Feb 2022 → Jun 2024 | neoplasm | Bio-Thera Solutions | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06376136 | May 2024 → Nov 2026 expected | cancer | Bio-Thera Solutions | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT1006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06376136 ↗ |
| Modality | Monoclonal antibody | “Recombinant humanized anti-HER2 monoclonal antibody for injection” NCT05414136 ↗ |
| Route | Intravenous | “Intravenous” NCT06376136 ↗ |